down arrow

IGC Pharma, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US45408X3089
USD
0.31
0 (1.36%)

Dec 04

ASE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.300.31

52 Week

0.250.50
Valuation
Technical
Day's Volume

CASH

446.88 k

Shareholding (Jun 2025)

FII

0.03%

Held by 4 FIIs

DII

98.21%

Held by 2 DIIs

Promoter

0.00%

How big is IGC Pharma, Inc.?

22-Jun-2025

As of Jun 18, IGC Pharma, Inc. has a market capitalization of 23.91 million and reported net sales of 1.23 million with a net profit of -8.81 million over the last four quarters. The company has shareholder's funds of 7.32 million and total assets of 9.90 million as of Mar 24.

Market Cap: As of Jun 18, IGC Pharma, Inc. has a market capitalization of 23.91 million, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, IGC Pharma, Inc. reported net sales of 1.23 million and a net profit of -8.81 million.<BR><BR>Balance Sheet Snapshot: As of Mar 24, the company reported shareholder's funds of 7.32 million and total assets of 9.90 million.

Read More

What does IGC Pharma, Inc. do?

22-Jun-2025

IGC Pharma, Inc. develops phytocannabinoid-based therapies for serious health conditions and operates in the Pharmaceuticals & Biotechnology industry with a market cap of approximately $23.91 million. As of December 2024, the company reported net sales of $0 million and a net loss of $2 million.

Overview:<BR>IGC Pharma, Inc. develops intellectual property for the treatment of life-altering or life-threatening conditions through research on phytocannabinoid-based therapies, operating in the Pharmaceuticals & Biotechnology industry with a micro-cap market classification.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Million (Quarterly Results - Dec 2024)<BR>Most recent Net Profit: -2 Million (Quarterly Results - Dec 2024)<BR>Market-cap: USD 23.91 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -0.03<BR>Return on Equity: -129.21%<BR>Price to Book: 3.82<BR><BR>Contact Details:<BR>Address: 10224 FALLS ROAD, POTOMAC MD: 20854<BR>Tel: 1 301 9830998<BR>Fax: 1 240 4650273<BR>Website: http://www.igcinc.us

Read More

Who are in the management team of IGC Pharma, Inc.?

22-Jun-2025

As of March 2022, the management team of IGC Pharma, Inc. includes Mr. Richard Prins as the Independent Chairman of the Board and Mr. John Lynch as a Director.

As of March 2022, the management team of IGC Pharma, Inc. includes Mr. Richard Prins, who serves as the Independent Chairman of the Board, and Mr. John Lynch, who is a Director.

Read More

Is IGC Pharma, Inc. overvalued or undervalued?

20-Sep-2025

As of August 10, 2023, IGC Pharma, Inc. is considered risky and overvalued due to poor financial metrics, including a Price to Book Value of 3.90 and negative EV ratios, despite a strong year-to-date return of 22.59%, which contrasts sharply with its long-term performance of -65.39% over five years.

As of 10 August 2023, IGC Pharma, Inc. has moved from a grade of does not qualify to risky. The company is overvalued based on its current financial metrics. Key ratios include a Price to Book Value of 3.90, an EV to EBIT of -2.95, and an EV to EBITDA of -3.21, indicating significant operational challenges and a lack of profitability. In comparison, peers such as Equillium, Inc. have an EV to EBITDA of -4.94, and OncoCyte Corp. stands at -2.13, suggesting that IGC Pharma's valuation is less favorable relative to its peers.<BR><BR>Despite a strong year-to-date return of 22.59% compared to the S&P 500's 12.22%, the overall long-term performance remains concerning, with a 5-year return of -65.39% versus the S&P 500's 96.61%. This discrepancy highlights the risks associated with investing in IGC Pharma, reinforcing the conclusion that the stock is overvalued.

Read More

Is IGC Pharma, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, IGC Pharma, Inc. shows a mildly bullish trend with mixed technical indicators, outperforming the S&P 500 in the short term but underperforming over longer periods.

As of 2 September 2025, the technical trend for IGC Pharma, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages indicate a bullish stance, but the weekly RSI is bearish. Bollinger Bands show a mildly bullish trend on both weekly and monthly time frames. The KST is bullish weekly but bearish monthly, and the OBV is bullish monthly with no trend weekly. <BR><BR>In terms of performance, IGC Pharma has outperformed the S&P 500 over the past week (1.98% vs. 1.05%) and month (8.37% vs. 2.33%), as well as year-to-date (22.59% vs. 12.22%) and over the past year (21.15% vs. 17.14%). However, it has significantly underperformed over the longer terms of 3 years, 5 years, and 10 years. Overall, the current stance is mildly bullish, with mixed signals from various indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 38 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.04

stock-summary
Return on Equity

-104.34%

stock-summary
Price to Book

6.20

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-30.11%
0%
-30.11%
6 Months
0.16%
0%
0.16%
1 Year
-14.83%
0%
-14.83%
2 Years
-4.34%
0%
-4.34%
3 Years
-30.26%
0%
-30.26%
4 Years
-73.15%
0%
-73.15%
5 Years
-84.62%
0%
-84.62%

IGC Pharma, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is IGC Pharma, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for IGC Pharma, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages indicate a bullish stance, but the weekly RSI is bearish. Bollinger Bands show a mildly bullish trend on both weekly and monthly time frames. The KST is bullish weekly but bearish monthly, and the OBV is bullish monthly with no trend weekly. In terms of performance, IGC Pharma has outperformed the S&P 500 over the past week (1.98% vs. 1.05%) and month (8.37% vs. 2.33%), as well as year-to-date (22.59% vs. 12.22%) and over the past year (21.15% vs. 17.14%). However, it has significantly underperformed over the longer terms of 3 years, 5 years, and 10 years. Overall, the current stance is mildly bullish, with mixed signals from various indicators....

Read More

Is IGC Pharma, Inc. overvalued or undervalued?

As of 10 August 2023, IGC Pharma, Inc. has moved from a grade of does not qualify to risky. The company is overvalued based on its current financial metrics. Key ratios include a Price to Book Value of 3.90, an EV to EBIT of -2.95, and an EV to EBITDA of -3.21, indicating significant operational challenges and a lack of profitability. In comparison, peers such as Equillium, Inc. have an EV to EBITDA of -4.94, and OncoCyte Corp. stands at -2.13, suggesting that IGC Pharma's valuation is less favorable relative to its peers. Despite a strong year-to-date return of 22.59% compared to the S&P 500's 12.22%, the overall long-term performance remains concerning, with a 5-year return of -65.39% versus the S&P 500's 96.61%. This discrepancy highlights the risks associated with investing in IGC Pharma, reinforcing the conclusion that the stock is overvalued....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-15.07%
EBIT Growth (5y)
1.01%
EBIT to Interest (avg)
-10.60
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.03
Sales to Capital Employed (avg)
0.14
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
4.48%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.90
EV to EBIT
-2.95
EV to EBITDA
-3.21
EV to Capital Employed
4.00
EV to Sales
19.60
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-135.60%
ROE (Latest)
-129.21%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (1.76%)

Foreign Institutions

Held by 4 Foreign Institutions (0.03%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs -50.00% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 33.33% vs -14.29% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.80",
          "val2": "-2.20",
          "chgp": "18.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.60",
          "val2": "-2.40",
          "chgp": "33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-5,807.90%",
          "val2": "-8,808.80%",
          "chgp": "300.09%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 0.00% vs 44.44% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 45.38% vs -13.04% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.30",
          "val2": "1.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.80",
          "val2": "-9.20",
          "chgp": "26.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-3.30",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.10",
          "val2": "-13.00",
          "chgp": "45.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-5,858.40%",
          "val2": "-7,284.80%",
          "chgp": "142.64%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.30
0.30
Operating Profit (PBDIT) excl Other Income
-1.80
-2.20
18.18%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.60
-2.40
33.33%
Operating Profit Margin (Excl OI)
-5,807.90%
-8,808.80%
300.09%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs -50.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 33.33% vs -14.29% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
1.30
1.30
Operating Profit (PBDIT) excl Other Income
-6.80
-9.20
26.09%
Interest
0.00
0.00
Exceptional Items
0.00
-3.30
100.00%
Consolidate Net Profit
-7.10
-13.00
45.38%
Operating Profit Margin (Excl OI)
-5,858.40%
-7,284.80%
142.64%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 0.00% vs 44.44% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 45.38% vs -13.04% in Mar 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About IGC Pharma, Inc. stock-summary
stock-summary
IGC Pharma, Inc.
Pharmaceuticals & Biotechnology
India Globalization Capital, Inc. develops intellectual property for the treatment of life altering or life threatening conditions, through its research on phytocannabinoid-based therapies, in the United States. The Company also builds farming facilities for leasing. In Malaysia, the Company develops and manages residential and commercial real estate. In India, it leases heavy equipment. It is also focused on developing, testing and patenting phytocannabinoid-based pharmaceutical therapies and becoming a specialty pharmaceutical provider of phytocannabinoid-based pharmaceutical and nutraceutical products. It is developing a product portfolio of phytocannabinoid-based therapies for indications, including neuropathic and cancer pain, epilepsy, end of life supportive care, adjunctive supportive therapies of chronic neurological and oncological diagnosis. In Malaysia, the Company’s subsidiary, Cabaran Ultima Sdn. Bhd., is focused on building a five-star hotel, Genting highlands.
Company Coordinates stock-summary
Company Details
10224 FALLS ROAD , POTOMAC MD : 20854
stock-summary
Tel: 1 301 9830998
stock-summary
http://www.igcinc.us
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."